Annexin Pharmaceuticals AB

As of June 30, 2026, Annexin Pharmaceuticals AB carries a market capitalization of 85.06M, placing it among publicly traded companies globally. Its enterprise value stands at 79.79M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Annexin Pharmaceuticals AB has 7.06M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Annexin Pharmaceuticals AB maintains a current ratio of 1.19, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Annexin Pharmaceuticals AB posted a negative return on equity (ROE) of -177.51, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -148.86, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 4.00, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Annexin Pharmaceuticals AB's stock has declined approximately 69.23% over the past 52 weeks. The 50-day moving average sits at 11.04, while the 200-day moving average is 13.32.

Over the twelve months ended June 30, 2026, Annexin Pharmaceuticals AB generated - - in revenue and converted that into -42.49M in net income, yielding earnings per share of -6.18. EBITDA reached -42.91M, while operating income came in at -43.18M.

As of June 30, 2026, Annexin Pharmaceuticals AB holds 5.27M in cash and equivalents against - - in total debt, resulting in a net debt position of -5.27M. Total book value stands at 2.52M, with working capital of 1.03M providing operational flexibility.

Annexin Pharmaceuticals AB produced -40.52M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -129,000.00 in capital expenditures, free cash flow totaled -40.65M - equivalent to -5.91 per share.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -49.08: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.39, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Annexin Pharmaceuticals AB shareholders.

Annexin Pharmaceuticals AB's most recent stock split took place on June 10, 2026 with a 397:403 split ratio.

As of June 30, 2026, Annexin Pharmaceuticals AB has an Altman Z-Score of -78.84, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.